One of the main causes of cervical cancer is persistent human papillomavirus (HPV) infection, with E6 and E7 being the main oncogenic genes of HPV3. For this reason, targeting HPV proteins E6 and E7 is a promising therapeutic strategy for the treatment of this disease.
Peptidream Inc. and Modulus Discovery Inc. have nominated the first clinical development candidate arising from the companies’ strategic drug discovery partnership.
Lawrence Livermore National Laboratory, Leidos Biomedical Research Inc. and Theras Inc. have jointly patented GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.
A Design Therapeutics Inc. patent details conjugates consisting of DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence linked to protein binding moiety through oligomeric backbone linker.
Research at Blossomhill Therapeutics Inc. has led to the discovery of new macrocyclic compounds acting as tyrosine kinase inhibitors and reported to be useful for the treatment of autoimmune disease.
Beijing Scitech-MQ Pharmaceuticals Ltd. described receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors reported to be useful for the treatment of cancer.
China Pharmaceutical University and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have patented benzimidazole compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, infections, autoimmune disease and inflammatory disorders.
Researchers from Interius Biotherapeutics Inc. presented the development and preclinical evaluation of a novel gene therapy candidate, INT-2104, as potential candidate for the treatment of B-cell malignancies.
Researchers from China Pharmaceutical University and affiliated organizations have reported the discovery and preclinical evaluation of a novel bromodomain and extra-terminal (BET) inhibitor, DDO-8926, being developed for the management of neuropathic pain.
Agios Pharmaceuticals Inc. and Alnylam Pharmaceuticals Inc. have entered into an exclusive worldwide license agreement under which Agios will acquire the rights to develop and commercialize Alnylam’s novel preclinical siRNA targeting TMPRSS6, as a potential disease-modifying treatment for patients with polycythemia vera (PV).
RSS
